On Friday, a comprehensive U.S. study revealed that the use of Novo Nordisk A/S’s (MYSE: NVO) drugs Ozempic and Wegovy, widely prescribed for type 2 diabetes and obesity, respectively, is not associated with an increased risk of suicidal thoughts. Contrary to previous concerns, the research found a lower incidence of such thoughts among users of these drugs compared to other treatments. Both Ozempic and Wegovy contain semaglutide, a GLP-1 agonist, which has been under scrutiny after reports of suicidal ideation in patients. The study, funded by the U.S. National Institutes of Health and publis…
